Benjamin Petsch | Senior Director Infectious Diseases Research
CureVac AG

Benjamin Petsch, Senior Director Infectious Diseases Research, CureVac AG

Dr. Benjamin Petsch, Senior Director Infectious Disease Research at CureVac AG. His responsibility is the pre-clinical research and development of mRNA-based prophylactic vaccines using CureVac’s RNActive technology. He received his university degree in biology from University of Munich and performed his doctoral thesis on the generation of monoclonal antibodies at the Institute of Immunology of the Friedrich-Loeffler-Institut, Tuebingen, where he continued as a postdoc and then as a research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. He joined CureVac in 2010 as a scientist in the department of Vaccines developing mRNA based vaccines against infectious diseases and is leading this department since 2013. Dr. Petsch performed the ADVAC training in 2018 and is inventor on several patent applications on mRNA based vaccination and author of several scientific articles on infectious disease research.


Pre-congress Workshops, April 6 @ 10:00


The role of vaccines in preventing outbreaks, through natural causes or biothreatsIt only takes natural outbreaks and bioterrorism attacks like the Ebola and anthrax to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.
  • NIAID’s gap filling preclinical services for vaccine development
  • Expanding the utility of biodefense vaccines
  • Biodefense and Pandemic Preparedness:Two sides of the same coin?
  • Update on the broadly neutralizing influenza monoclonal antibody used for the DARPA-funded Pandemic Preparedness Platform (P3) initiative
  • A disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates